Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 80

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The DNA-binding domain mediates both nuclear and cytosolic functions of p53

Follis, Ariele Viacava, Llambi, Fabien, Ou, Li, Baran, Katherine, Green, Douglas R, Kriwacki, Richard W·2014·Nature Structural & Molecular Biology
DOI 10.1038/nsmb.2829
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nsmb.2829

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 55

  1. Leu, J.I., Dumont, P., Hafey, M., Murphy, M.E. & George, D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex. Nat. Cell Biol. 6, 443–450 (2004). · DOI · Paper page
  2. Chipuk, J.E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D.D. & Green, D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309, 1732–1735 (2005). · DOI · Paper page
  3. Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997). · DOI · Paper page
  4. Petros, A.M. et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9, 2528–2534 (2000). · doi:10.1110/ps.9.12.2528 · Paper page
  5. Feng, W., Huang, S., Wu, H. & Zhang, M. Molecular basis of Bcl-xL's target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin-1. J. Mol. Biol. 372, 223–235 (2007). · DOI · Paper page
  6. Liu, X., Dai, S., Zhu, Y., Marrack, P. & Kappler, J.W. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 19, 341–352 (2003). · DOI · Paper page
  7. Cheng, E.H. et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8, 705–711 (2001). · DOI · Paper page
  8. Wang, P. et al. p53 domains: structure, oligomerization, and transformation. Mol. Cell. Biol. 14, 5182–5191 (1994). · DOI · Paper page
  9. Petros, A.M., Gunasekera, A., Xu, N., Olejniczak, E.T. & Fesik, S.W. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett. 559, 171–174 (2004). · DOI
  10. Sot, B., Freund, S.M. & Fersht, A.R. Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J. Biol. Chem. 282, 29193–29200 (2007). · DOI
  11. Hagn, F. et al. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J. Biol. Chem. 285, 3439–3450 (2010). · DOI
  12. Yao, H. et al. Anti-apoptosis proteins Mcl-1 and Bcl-xL have different p53-binding profiles. Biochemistry 52, 6324–6334 (2013). · DOI
  13. Di Lello, P. et al. Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell 22, 731–740 (2006). · DOI · Paper page
  14. Lee, C.W., Martinez-Yamout, M.A., Dyson, H.J. & Wright, P.E. Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry 49, 9964–9971 (2010). · DOI · Paper page
  15. Xu, H., Tai, J., Ye, H., Kang, C.B. & Yoon, H.S. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl. Biochem. Biophys. Res. Commun. 341, 938–944 (2006). · DOI
  16. Xu, H. et al. The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif. Biochemistry 48, 12159–12168 (2009). · DOI
  17. Ha, J.H. et al. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways. J. Biol. Chem. 288, 7387–7398 (2013). · DOI
  18. Livingstone, L.R. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923–935 (1992). · DOI · Paper page
  19. Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345–347 (1991). · DOI · Paper page
  20. Mietz, J.A., Unger, T., Huibregtse, J.M. & Howley, P.M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11, 5013–5020 (1992). · DOI · Paper page
  21. Schultz, L.B., Chehab, N.H., Malikzay, A. & Halazonetis, T.D. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151, 1381–1390 (2000). · DOI · Paper page
  22. Pervushin, K., Riek, R., Wider, G. & Wuthrich, K. Attenuated T-2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA 94, 12366–12371 (1997). · DOI · Paper page
  23. Muchmore, S.W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335–341 (1996). · DOI · Paper page
  24. Joerger, A.C., Allen, M.D. & Fersht, A.R. Crystal structure of a superstable mutant of human p53 core domain: insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. 279, 1291–1296 (2004). · DOI · Paper page
  25. Follis, A.V. et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat. Chem. Biol. 9, 163–168 (2013). · DOI · Paper page
  26. Galea, C., Bowman, P. & Kriwacki, R.W. Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils. Protein Sci. 14, 2993–3003 (2005). · DOI
  27. Johnson, C.R., Morin, P.E., Arrowsmith, C.H. & Freire, E. Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor-suppressor. Biochemistry 34, 5309–5316 (1995). · DOI
  28. Kitayner, M. et al. Structural basis of DNA recognition by p53 tetramers. Mol. Cell 22, 741–753 (2006). · DOI · Paper page
  29. Chipuk, J.E., Moldoveanu, T., Llambi, F., Parsons, M.J. & Green, D.R. The BCL-2 family reunion. Mol. Cell 37, 299–310 (2010). · DOI · Paper page
  30. Hollstein, M. et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551–3555 (1994).
  31. Hernandez-Boussard, T., Rodriguez-Tome, P., Montesano, R. & Hainaut, P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. Hum. Mutat. 14, 1–8 (1999). · doi:10.1002/(sici)1098-1004(1999)14:1<1::aid-humu1>3.0.co;2-h
  32. Bullock, A.N. et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 94, 14338–14342 (1997). · DOI · Paper page
  33. Inga, A. & Resnick, M.A. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 20, 3409–3419 (2001). · DOI
  34. Bullock, A.N., Henckel, J. & Fersht, A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245–1256 (2000). · DOI · Paper page
  35. Kato, S. et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA 100, 8424–8429 (2003). · DOI · Paper page
  36. Weinberg, R.L., Veprintsev, D.B. & Fersht, A.R. Cooperative binding of tetrameric p53 to DNA. J. Mol. Biol. 341, 1145–1159 (2004). · DOI · Paper page
  37. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 253, 49–53 (1991). · DOI · Paper page
  38. Joo, W.S. et al. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev. 16, 583–593 (2002). · DOI · Paper page
  39. Gorina, S. & Pavletich, N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001–1005 (1996). · DOI · Paper page
  40. Lilyestrom, W., Klein, M.G., Zhang, R., Joachimiak, A. & Chen, X.S. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 20, 2373–2382 (2006). · DOI · Paper page
  41. Kuwana, T. et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111, 331–342 (2002). · DOI · Paper page
  42. Asciolla, J.J., Renault, T.T. & Chipuk, J.E. Examining BCL-2 family function with large unilamellar vesicles. J. Vis. Exp. 10.3791/4291(5 October 2012). · DOI
  43. Llambi, F. et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 44, 517–531 (2011). · DOI · Paper page
  44. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005). · DOI · Paper page
  45. Miyashita, T. & Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293–299 (1995). · DOI · Paper page
  46. Wang, Y., Filippov, I., Richter, C., Luo, R. & Kriwacki, R.W. Solution NMR studies of an intrinsically unstructured protein within a dilute, 75 kDa eukaryotic protein assembly; probing the practical limits for efficiently assigning polypeptide backbone resonances. ChemBioChem 6, 2242–2246 (2005). · DOI
  47. Bell, S., Hansen, S. & Buchner, J. Refolding and structural characterization of the human p53 tumor suppressor protein. Biophys. Chem. 96, 243–257 (2002). · DOI
  48. Keller, R.J.J. Optimizing the process of nuclear magnetic resonance spectrum analysis and computer aided resonance assignment. PhD thesis, Eidgenossische Technishe Hochschule (2005).
  49. Güntert, P. Automated NMR structure calculation with CYANA. Methods Mol. Biol. 278, 353–378 (2004).
  50. de Vries, S.J., van Dijk, M. & Bonvin, A.M. The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5, 883–897 (2010). · DOI · Paper page
  51. Simon, B., Madl, T., Mackereth, C.D., Nilges, M. & Sattler, M. An efficient protocol for NMR-spectroscopy-based structure determination of protein complexes in solution. Angew. Chem. Int. Ed. Engl. 49, 1967–1970 (2010). · DOI
  52. Wang, Y., Rosengarth, A. & Luecke, H. Structure of the human p53 core domain in the absence of DNA. Acta Crystallogr. D Biol. Crystallogr. 63, 276–281 (2007). · DOI
  53. Reynolds, C., Damerell, D. & Jones, S. ProtorP: a protein-protein interaction analysis server. Bioinformatics 25, 413–414 (2009). · DOI · Paper page
  54. Saha, R.P., Bahadur, R.P., Pal, A., Mandal, S. & Chakrabarti, P. ProFace: a server for the analysis of the physicochemical features of protein-protein interfaces. BMC Struct. Biol. 6, 11 (2006). · DOI
  55. Gabdoulline, R.R., Wade, R.C. & Walther, D. MolSurfer: a macromolecular interface navigator. Nucleic Acids Res. 31, 3349–3351 (2003). · DOI

Cited by

See all 80

Metadata

Authors
Follis, A. V., Llambi, F., Ou, L., Baran, K., Green, D. R., & Kriwacki, R. W.
Venue
Nature Structural & Molecular Biology
Publisher
Springer Science and Business Media LLC
Published
2014-05-11
Volume
21
Issue
6
Pages
535-543
ISSN
  • 1545-9993
  • 1545-9985
DOI
10.1038/nsmb.2829
Cited by
80
References
9
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.